Market Cap 2.80B
Revenue (ttm) 399.36M
Net Income (ttm) -151.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 57.94
Profit Margin -37.96%
Debt to Equity Ratio 2.18
Volume 1,610,100
Avg Vol 2,558,298
Day's Range N/A - N/A
Shares Out 298.81M
Stochastic %K 83%
Beta 0.62
Analysts Strong Sell
Price Target $17.09

Latest News on FOLD

3 Oversold Biotech Names

Jan 13, 2025, 12:56 PM EST - 4 days ago

3 Oversold Biotech Names

AVDL JAZZ VKTX XBI


Amicus Therapeutics: Cheap Heading Into 2025

Dec 27, 2024, 1:33 PM EST - 21 days ago

Amicus Therapeutics: Cheap Heading Into 2025


3 Attractive Biotechs With Recent Positives

Oct 21, 2024, 4:17 PM EDT - 3 months ago

3 Attractive Biotechs With Recent Positives

EXEL MRK TEVA XBI


Amicus: Teva Settlement Clears Revenue Path Forward For Galafold

Oct 18, 2024, 3:47 PM EDT - 3 months ago

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold


'Boring' Amicus Therapeutics Is Making Progress

Sep 29, 2024, 2:44 AM EDT - 3 months ago

'Boring' Amicus Therapeutics Is Making Progress


3 'Repeatable' Biotech Trades

Sep 25, 2024, 12:46 PM EDT - 4 months ago

3 'Repeatable' Biotech Trades

DVAX GSK NTLA XBI


3 Biotech Names Under $10 I Own

Jun 2, 2024, 10:18 AM EDT - 8 months ago

3 Biotech Names Under $10 I Own

AUPH VYGR


Amicus Therapeutics: Too Cheap At Under $10 A Share

May 20, 2024, 5:06 AM EDT - 8 months ago

Amicus Therapeutics: Too Cheap At Under $10 A Share


Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

Feb 29, 2024, 10:05 AM EST - 11 months ago

Amicus Therapeutics: Expect Improved Commercial Momentum In 2024


Amicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 1:07 PM EST - 11 months ago

Amicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call Transcript